Enteric glial reactivity to systemic LPS administration: Changes in GFAP and S100B protein

Publication date: Available online 4 January 2017
Source:Neuroscience Research
Author(s): Raphaela da Cunha Franceschi, Patrícia Nardin, Clivia Valle Machado, Lucas Silva Tortorelli, Malcon Andrei Martinez-Pereira, Carolline Zanotto, Carlos Alberto Gonçalves, Denise Maria Zancan
Lipopolysaccharide (LPS) is used to induce inflammation and promotes nervous system activation. Different regions of the brain present heterogeneous glial responses; thus, in order to verify whether systemic LPS-induced inflammation affects the enteric glia differently across the intestinal segments, we evaluated the expressions of two glial activity markers, GFAP and S100B protein, in different intestine segments, at 1h, 24h and 7days after acute systemic LPS administration (0.25 or 2.5mg kg–1) in rats. Histological inflammatory analysis indicated that the cecum was most affected when compared to the duodenum and proximal colon at the highest doses of LPS. LPS induced an increased S100B content after 24h in all three regions, which decreased at 7days after the highest dose in all regions. Moreover, at 24h, this dose of LPS increased ex-vivo S100B secretion only in the cecum. The highest dose of LPS also increased GFAP in all regions at 24h, but earlier in the cecum, where LPS-induced enteric S100B and GFAP alterations were dependent on dose, time and intestine region. No associated changes in serum S100B were observed. Our results indicate heterogeneous enteric glial responses to inflammatory insult, as observed in distinct brain areas.



http://ift.tt/2iSGMem